Femara, Letrozole News

W R Miller 1 , A Larionov 1 , T J Anderson 1 , D B Evans 2 and J M Dixon 1 Correspondence: Professor WR Miller, 2 Stoneycroft Road, South Queensferry EH30 9HX, UK.

A group of widely heralded drugs used to treat breast cancer patients to prevent recurrence of tumors , is now proving troublesome for many women who have to take them.

The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according to new data from the ZO-FAST trial.

2, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.